Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Aghi
Manish
M
Department of Neurosurgery, Massachusetts General Hopsital, Harvard Medical School, Charlestown, USA.
Rabkin
Samuel
S
Martuza
Robert L
RL
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000235:genetics / Q000628:therapy*; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D015254:DNA Modification Methylases / Q000502:physiology; D045643:DNA Repair Enzymes / Q000502:physiology; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016158:Genes, p53 / Q000235:genetics; D005910:Glioma / Q000235:genetics / Q000628:therapy*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D050130:Oncolytic Virotherapy; D018139:Simplexvirus / Q000235:genetics; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000502:physiology
D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide